Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Lasa M, et al. Among authors: cabanas v. J Clin Oncol. 2024 Oct 1:JCO2400635. doi: 10.1200/JCO.24.00635. Online ahead of print. J Clin Oncol. 2024. PMID: 39353166
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.
Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jelínek T, Johnson S, Milani P, Cordon L, Perez JJ, Lasa M, Termini R, Oriol A, Hernandez MT, Palomera L, Martinez-Martinez R, de la Rubia J, de Arriba F, Rios R, Gonzalez ME, Gironella M, Cabañas V, Casanova M, Krsnik I, Perez-Montaña A, González-Calle V, Rodriguez-Otero P, Maisnar V, Hajek R, Van Rhee F, Jimenez-Zepeda V, Palladini G, Merlini G, Orfao A, de la Cruz J, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San-Miguel JF, Paiva B; PETHEMA/GEM Cooperative Group. Burgos L, et al. Among authors: cabanas v. J Clin Oncol. 2023 Jun 1;41(16):3019-3031. doi: 10.1200/JCO.22.01916. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930848
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
Puig N, Paiva B, Lasa M, Burgos L, Perez JJ, Merino J, Moreno C, Vidriales MB, Toboso DG, Cedena MT, Ocio EM, Lecumberri R, García de Coca A, Labrador J, Gonzalez ME, Palomera L, Gironella M, Cabañas V, Casanova M, Oriol A, Krsnik I, Pérez-Montaña A, de la Rubia J, de la Puerta JE, de Arriba F, Prosper F, Martinez-Lopez J, Lecrevisse Q, Verde J, Mateos MV, Lahuerta JJ, Orfao A, San Miguel JF. Puig N, et al. Among authors: cabanas v. Leukemia. 2019 May;33(5):1256-1267. doi: 10.1038/s41375-018-0308-5. Epub 2018 Dec 12. Leukemia. 2019. PMID: 30542145
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
Lahuerta JJ, Jiménez-Ubieto A, Paiva B, Martínez-López J, González-Medina J, López-Anglada L, Cedena MT, Puig N, Oriol A, Blanchard MJ, Ríos R, Martin J, Martínez R, Sureda A, Hernández MT, de la Rubia J, Krsnik I, Cabañas V, Palomera L, Bargay J, Mateos MV, Rosiñol L, San Miguel JF, Blade J. Lahuerta JJ, et al. Among authors: cabanas v. Blood. 2019 Jun 20;133(25):2664-2668. doi: 10.1182/blood.2019000671. Epub 2019 Apr 22. Blood. 2019. PMID: 31010846 Free article.
Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma.
Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Alonso R, et al. Among authors: cabanas v. Am J Hematol. 2019 Aug;94(8):853-861. doi: 10.1002/ajh.25507. Epub 2019 Jun 9. Am J Hematol. 2019. PMID: 31074033 Free article.
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.
Puig N, Contreras MT, Agulló C, Martínez-López J, Oriol A, Blanchard MJ, Ríos R, Martín J, Iñigo MB, Sureda A, Hernández MT, de la Rubia J, González-Calle V, Krsnik I, Cabañas V, Palomera L, Moraleda JM, Bargay J, Cedena MT, Paiva B, Rosiñol L, Bladé J, San Miguel J, Lahuerta JJ, Mateos MV. Puig N, et al. Among authors: cabanas v. Blood Adv. 2022 Jun 14;6(11):3234-3239. doi: 10.1182/bloodadvances.2021006762. Blood Adv. 2022. PMID: 35157768 Free PMC article. Clinical Trial.
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
Termini R, Žihala D, Terpos E, Perez-Montaña A, Jelínek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodriguez S, Moreno C, Perez C, Maia C, Martín-Sánchez E, Guerrero C, Botta C, Garces JJ, Lopez A, Tamariz-Amador LE, Prosper F, Bargay J, Cabezudo ME, Ocio EM, Hájek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A, Geraldes C, Vitoria H, Gomez C, De Arriba F, Ludwig H, Garcia-Guiñon A, Casanova M, Alegre A, Cabañas V, Sirvent M, Oriol A, de la Rubia J, Hernández-Rivas JÁ, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B; PETHEMA/GEM and iMMunocell Cooperative Groups. Termini R, et al. Among authors: cabanas v. Clin Cancer Res. 2022 Nov 1;28(21):4771-4781. doi: 10.1158/1078-0432.CCR-22-1594. Clin Cancer Res. 2022. PMID: 36074126
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosiñol L, Oriol A, Ríos R, Blanchard MJ, Jarque I, Bargay J, Hernández MT, Cabañas V, Carrillo-Cruz E, Sureda A, Martínez-López J, Krsnik I, González ME, Casado LF, Martí JM, Encinas C, de Arriba F, Palomera L, Sampol A, González-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San Miguel J, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: cabanas v. Blood. 2023 Nov 2;142(18):1518-1528. doi: 10.1182/blood.2022019531. Blood. 2023. PMID: 37506339 Free article. Clinical Trial.
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.
Puig N, Agullo Roca C, Sanfeliciano TC, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos-Tamayo R, Iñigo Rodríguez B, Sureda A, Lakhwani S, de la Rubia Comos J, Gonzalez-Calle V, Cabañas V, Palomera L, Moraleda JMM, Bargay J, Castro S, Rosiñol L, Bladé J, San-Miguel JF, Lahuerta JJ, Paiva B, Mateos MV. Puig N, et al. Among authors: cabanas v. Blood. 2024 Sep 18:blood.2024024995. doi: 10.1182/blood.2024024995. Online ahead of print. Blood. 2024. PMID: 39293025
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.
de Arriba de la Fuente F, Durán MS, Álvarez MÁ, Sanromán IL, Dios AM, Ríos Tamayo R, García R, González MS, Prieto E, Bárez A, Escalante F, Tejedor A, Ballesteros M, Cabañas V, Capote FJ, Couto C, Garzón S, González-Pardo M, Mateos Manteca MV. de Arriba de la Fuente F, et al. Among authors: cabanas v. Semin Hematol. 2018 Oct;55(4):189-196. doi: 10.1053/j.seminhematol.2017.09.002. Epub 2017 Oct 13. Semin Hematol. 2018. PMID: 30502846 Review.
31 results